["{\n\"step_by_step_thinking\": \"According to the provided documents, Mitoxantrone as a single agent has shown therapeutic efficacy similar to that of standard induction and salvage treatment regimens in advanced breast cancer. In one study, 17% of patients achieved an overall response rate when treated with Mitoxantrone alone. Additionally, another study showed that weekly low-dose Mitoxantrone plus Doxorubicin as second-line chemotherapy had a partial response rate of 14%. These studies suggest that single-agent Mitoxantrone has significant activity in breast cancer, which is comparable to the efficacy seen with combination chemotherapy regimens.\",\n\"answer_choice\": B"]